Bausch + Lomb receives Canadian approval for enVista Envy IOL
Click Here to Manage Email Alerts
Key takeaways:
- Bausch + Lomb expects the enVista Envy IOL to be commercially available in Canada in mid-June.
- The company is working on regulatory approval in the U.S.
Health Canada approved the enVista Envy full visual range IOL, the first global approval for the lens, according to a press release from Bausch + Lomb.
The lens helps optimize vision in any lighting condition with its ActivSync Optic Intelligent Energy Distribution and reduces light scattering with its ClearPath technology, according to the release.
“The enVista platform is well-known and highly trusted by ophthalmologists,” Anthony Wallace, vice president and general manager, North America, Bausch + Lomb Surgical, told Healio. “In fact, cataract surgeons have performed more than 6 million surgeries worldwide using the enVista platform. enVista Envy gives doctors in Canada access to the first premium, full range of vision enVista IOL.”
The enVista Envy IOL demonstrated positive long-term outcomes in a randomized controlled clinical trial in which 93% of patients reported little or no issues with dysphotopsia. The lens also provided good distance vision without glasses, and 94% of patients reported little or no difficultly viewing close objects, according to the release.
“It also offers low-cylinder correction offerings for toric patients, giving ophthalmologists the ability to better meet the specific needs and high expectations of more patients, even those with low amounts of astigmatism,” Wallace said.
Bausch + Lomb expects the enVista Envy IOL to be commercially available in Canada by mid-June and is in the process of obtaining regulatory approvals globally.
“Later this year, we expect to have a decision from the FDA on enVista Envy approval in the United States. After that, we will work to pursue approval in other markets around the world,” Wallace said.
Collapse
Read more about
Click Here to Manage Email Alerts